189 related articles for article (PubMed ID: 11809696)
1. X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance.
Park SY; Lam W; Cheng YC
Cancer Res; 2002 Jan; 62(2):459-65. PubMed ID: 11809696
[TBL] [Abstract][Full Text] [Related]
2. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines.
Beidler DR; Chang JY; Zhou BS; Cheng YC
Cancer Res; 1996 Jan; 56(2):345-53. PubMed ID: 8542590
[TBL] [Abstract][Full Text] [Related]
3. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors.
Kuo CC; Liu JF; Chang JY
J Pharmacol Exp Ther; 2006 Feb; 316(2):946-54. PubMed ID: 16258022
[TBL] [Abstract][Full Text] [Related]
4. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
5. Preventing oxidation of cellular XRCC1 affects PARP-mediated DNA damage responses.
Horton JK; Stefanick DF; Gassman NR; Williams JG; Gabel SA; Cuneo MJ; Prasad R; Kedar PS; Derose EF; Hou EW; London RE; Wilson SH
DNA Repair (Amst); 2013 Sep; 12(9):774-85. PubMed ID: 23871146
[TBL] [Abstract][Full Text] [Related]
6. DNA polymerase β-dependent cell survival independent of XRCC1 expression.
Horton JK; Gassman NR; Dunigan BD; Stefanick DF; Wilson SH
DNA Repair (Amst); 2015 Feb; 26():23-9. PubMed ID: 25541391
[TBL] [Abstract][Full Text] [Related]
7. TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer.
Xu W; Wang S; Chen Q; Zhang Y; Ni P; Wu X; Zhang J; Qiang F; Li A; Røe OD; Xu S; Wang M; Zhang R; Zhou J
Cell Death Dis; 2014 Feb; 5(2):e1055. PubMed ID: 24525731
[TBL] [Abstract][Full Text] [Related]
8. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Janss AJ; Cnaan A; Zhao H; Shpilsky A; Levow C; Sutton L; Phillips PC
Anticancer Drugs; 1998 Aug; 9(7):641-52. PubMed ID: 9773809
[TBL] [Abstract][Full Text] [Related]
9. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
10. The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication.
Barrows LR; Holden JA; Anderson M; D'Arpa P
Mutat Res; 1998 Aug; 408(2):103-10. PubMed ID: 9739812
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
Yanase K; Sugimoto Y; Tsukahara S; Oh-Hara T; Andoh T; Tsuruo T
Jpn J Cancer Res; 2000 May; 91(5):551-9. PubMed ID: 10835501
[TBL] [Abstract][Full Text] [Related]
12. A novel role of XRCC1 in the functions of a DNA polymerase beta variant.
Bhattacharyya N; Banerjee S
Biochemistry; 2001 Jul; 40(30):9005-13. PubMed ID: 11467963
[TBL] [Abstract][Full Text] [Related]
13. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1.
Schreiber V; Amé JC; Dollé P; Schultz I; Rinaldi B; Fraulob V; Ménissier-de Murcia J; de Murcia G
J Biol Chem; 2002 Jun; 277(25):23028-36. PubMed ID: 11948190
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional repression of O6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N'-bis(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells.
Ma LC; Kuo CC; Liu JF; Chen LT; Chang JY
Mol Pharmacol; 2008 Aug; 74(2):517-26. PubMed ID: 18492797
[TBL] [Abstract][Full Text] [Related]
16. Unique biochemical, cytotoxic, and antitumor activity of camptothecin and 4beta-amino-4'-O-demethylepipodophyllotoxin conjugates.
Chang JY; Guo X; Chen HX; Jiang Z; Fu Q; Wang HK; Bastow KF; Zhu XK; Guan J; Lee KH; Cheng YC
Biochem Pharmacol; 2000 Mar; 59(5):497-508. PubMed ID: 10660116
[TBL] [Abstract][Full Text] [Related]
17. XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro.
Caldecott KW; Aoufouchi S; Johnson P; Shall S
Nucleic Acids Res; 1996 Nov; 24(22):4387-94. PubMed ID: 8948628
[TBL] [Abstract][Full Text] [Related]
18. Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions.
Plo I; Liao ZY; Barceló JM; Kohlhagen G; Caldecott KW; Weinfeld M; Pommier Y
DNA Repair (Amst); 2003 Oct; 2(10):1087-100. PubMed ID: 13679147
[TBL] [Abstract][Full Text] [Related]
19. Mcl-1 suppresses abasic site repair following bile acid-induced hepatic cellular DNA damage.
Yu H; Zhang X; Liu R; Li H; Xiao X; Zhou Y; Wei C; Yang M; Liao M; Zhao J; Xia Z; Liao Q
Tumour Biol; 2017 Jul; 39(7):1010428317712102. PubMed ID: 28681695
[TBL] [Abstract][Full Text] [Related]
20. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
